Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 AMPLIFICATION
(
ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/761
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/306
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Breast Cancer
- Evidence Direction
- Supports
- Drug
- Neratinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 20142587
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Neratinib | Sensitivity | true |